PH12018501318A1 - Polymorphic crystalline forms of obeticholic acid - Google Patents

Polymorphic crystalline forms of obeticholic acid

Info

Publication number
PH12018501318A1
PH12018501318A1 PH12018501318A PH12018501318A PH12018501318A1 PH 12018501318 A1 PH12018501318 A1 PH 12018501318A1 PH 12018501318 A PH12018501318 A PH 12018501318A PH 12018501318 A PH12018501318 A PH 12018501318A PH 12018501318 A1 PH12018501318 A1 PH 12018501318A1
Authority
PH
Philippines
Prior art keywords
crystalline forms
obeticholic acid
polymorphic crystalline
disease
useful
Prior art date
Application number
PH12018501318A
Other languages
English (en)
Inventor
Andre Steiner
Poulsen Heidi Waenerlund
Emilie Jolibois
Melissa Rewolinski
Ralf Gross
Emma Sharp
Fiona Dubas-Fisher
Alex Eberlin
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12018501318(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of PH12018501318A1 publication Critical patent/PH12018501318A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12018501318A 2015-12-22 2018-06-20 Polymorphic crystalline forms of obeticholic acid PH12018501318A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid
PCT/US2016/012651 WO2017111979A1 (fr) 2015-12-22 2016-01-08 Formes cristallines polymorphes de l'acide obéticholique

Publications (1)

Publication Number Publication Date
PH12018501318A1 true PH12018501318A1 (en) 2019-02-18

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018501318A PH12018501318A1 (en) 2015-12-22 2018-06-20 Polymorphic crystalline forms of obeticholic acid

Country Status (15)

Country Link
EP (1) EP3394081A1 (fr)
JP (1) JP2018538331A (fr)
KR (1) KR20180095070A (fr)
CN (1) CN108495858A (fr)
AU (1) AU2016375566A1 (fr)
BR (1) BR112018012590A2 (fr)
CA (1) CA3009149A1 (fr)
CL (1) CL2018001720A1 (fr)
CO (1) CO2018006701A2 (fr)
EA (1) EA201891491A1 (fr)
IL (1) IL259998A (fr)
MX (1) MX2018007776A (fr)
PH (1) PH12018501318A1 (fr)
SG (1) SG11201805235XA (fr)
WO (1) WO2017111979A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
WO2018211413A1 (fr) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Formes solides d'acide obéticholique et procédé de préparation associé
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CZ31099U1 (cs) * 2017-09-05 2017-10-17 Zentiva, K.S. Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
WO2019106043A1 (fr) 2017-11-29 2019-06-06 Hexal Ag Composition pharmaceutique comprenant de l'acide obéticholique
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113264972B (zh) * 2020-02-14 2024-07-12 四川科伦药物研究院有限公司 一种制备奥贝胆酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CA3047776C (fr) * 2012-06-19 2022-10-18 Intercept Pharmaceuticals, Inc. Preparation, utilisations et formes solides d'acide obeticholique
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
US10301350B2 (en) * 2014-11-19 2019-05-28 NZP UK Limited 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal FXR modulators
EP3221332B1 (fr) * 2014-11-19 2019-04-24 NZP UK Limited Stéroïdes 5.bêta.-6-alkyl-7-hydroxy-3-one utilisés en tant qu'intermédiaires pour la production de modulateurs de fxr stéroïdiens
EA034739B1 (ru) * 2014-11-19 2020-03-16 ЭнЗедПи ЮКей ЛИМИТЕД 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EA033603B1 (ru) * 2014-11-19 2019-11-08 Nzp Uk Ltd 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr

Also Published As

Publication number Publication date
EA201891491A1 (ru) 2018-11-30
BR112018012590A2 (pt) 2018-12-04
CO2018006701A2 (es) 2018-07-10
MX2018007776A (es) 2018-08-09
KR20180095070A (ko) 2018-08-24
EP3394081A1 (fr) 2018-10-31
JP2018538331A (ja) 2018-12-27
SG11201805235XA (en) 2018-07-30
CN108495858A (zh) 2018-09-04
WO2017111979A1 (fr) 2017-06-29
CA3009149A1 (fr) 2017-06-29
IL259998A (en) 2018-07-31
CL2018001720A1 (es) 2018-08-10
AU2016375566A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
PH12018501318A1 (en) Polymorphic crystalline forms of obeticholic acid
PH12014502835A1 (en) Preparation, uses and solid forms of obeticholic acid
IL293229B2 (en) Preparations and methods for inhibiting gene expression of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase))
HUS2100041I1 (hu) Eljárások és kompozíciók a glikolát-oxidáz (HAO1) kettõs szálú RNA általi specifikus gátlására
HRP20190270T1 (hr) C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze
EP3174550A4 (fr) Méthodes et compositions relatives au traitement de l'hypertension artérielle pulmonaire
GB2551964B (en) Method of treating biomass to remove RNA
EP3363783A4 (fr) Composition utilisable en vue du traitement de la maladie intestinale inflammatoire et de la dermatite atopique
EP3370714A4 (fr) Compositions et méthodes de traitement de troubles du métabolisme des acides gras
MX2016015577A (es) La teobromina o sus derivados para el tratamiento o la prevencion de la litiasis renal.
EP3251675A4 (fr) Prévention ou traitement de maladie de goutte ou d'acide urique